Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · View financials
Decision snapshot: INCY stock price vs CHD: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at CHD's multiple
Needs CHD P/E.
Implied fair value · at INCY's multiple
Needs INCY P/E.
Live quote
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: INCY FY 2025 (ended Dec 31, 2025) · CHD FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
INCYTE CORPORATION · implied price per share
Bear
-$7.58
Base
-$8.91
Bull
-$10.25
CHURCH & DWIGHT CO., INC. · implied price per share
Bear
$29.37
Base
$34.56
Bull
$39.74
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
3.83x
0.60x
Net debt / EBITDA
Leverage against operating earnings
9.31x
1.47x
Cash and equivalents
Liquid reserves on the balance sheet
$3.38B
$409.00M
Total debt
Interest-bearing obligations outstanding
$19.78B
$2.41B
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
AMGEN INC
INCY vs AMGN
GILEAD SCIENCES, INC.
INCY vs GILD
VERTEX PHARMACEUTICALS INC / MA
INCY vs VRTX
REGENERON PHARMACEUTICALS, INC.
INCY vs REGN
BIOGEN INC.
INCY vs BIIB
PROCTER & GAMBLE Co
INCY vs PG
COLGATE PALMOLIVE CO
INCY vs CL
KIMBERLY CLARK CORP
INCY vs KMB
ESTEE LAUDER COMPANIES INC
INCY vs EL
Live quote
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
Based on an earlier data snapshot. Review the filing dates below or refresh after signing in.
If you believe INCY can sustain 21.2% revenue growth while reducing its 9.3x net debt/EBITDA burden, then the stock is worth owning because its low P/E and strong margins could justify rerating; if leverage does not improve, the P/E-based upside is less reliable.
INCY trades at 18.3x P/E versus CHD at 31.7x, which would normally imply a meaningful valuation discount for INCY on earnings-based measures. However, INCY also trades at a richer 4.6x P/S versus CHD at 3.7x and 7.8x EV/Revenue versus 4.0x, suggesting the market is paying up for sales quality and growth but not fully rewarding the stock on enterprise value metrics.
Supporting Metrics
